AAPGV Ascentage Earnings per share increase in current year
Premium pricing for innovative leukemia drugs strengthens the market position of Ascentage Pharma Group (AAPGV). This chart on GURU.Markets provides a year-over-year EPS comparison, with the indicator currently standing at 74.70. The development of senolytic agents through partnerships with biopharma companies and its status as a global leader in targeted oncology ensure the brand's resilience.
Financial and market metric breakdowns for Ascentage Pharma Group International (AAPGV)
- market value and analyst target forecast:
- market capitalization data:
- business book valuation details:
- debt burden and liquidity indicators:
Total Debt to Capital Coefficient Ascentage Pharma Group|AAPGV - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio Ascentage Pharma|AAPGV - Company Aggregate Debts|Debts to Book Value Ascentage Pharma Group|AAPGV - Company Long-Term Debt|Company Short-Term Indebtedness Ascentage Pharma|Intermediate Liquidity Ratio ascentage.com
- company profitability and valuation multiples indicators:
AAPGV - Net Profit|Projected Future Earnings Ascentage Pharma Group|AAPGV - P/E Multiple|Forward Price to Earnings Multiple Ascentage Pharma Group|AAPGV - PEG Multiple|Company Value to EBITDA Ascentage Pharma Group International|AAPGV - Operating profit before deduction of amortization|Earnings per share for the trailing year Ascentage Pharma|AAPGV - Earnings per share for the last twelve months|Year-over-year net earnings per share trend for the last twelve months ascentage.com|AAPGV - Earnings growth in current year|Expected earnings per share trend next year Ascentage Pharma Group
- sales volume and revenue information:
Fundamental valuation:AAPGV Ascentage
Ascentage Pharma Group operates in the high-risk sector of targeted oncology drug development, characterized by capital-intensive clinical trials. Analyzing current year-over-year EPS dynamics, an investor can observe the percentage deviation of net income per share, which reveals the impact of raw material and logistics costs on the bottom line. The positive trend confirms the effectiveness of the patent strategy and the scalability of a model devoid of manufacturing capital expenditures.
Main competitors
Earnings per share growth rate in current year BeiGene Corp (ONC)|HALO (Halozyme Therapeutics, Inc.) - Earnings growth in current year|Earnings per share growth rate in current year revmed.com RVMD|Earnings growth in current year AAPG|Net earnings per share growth this year CG Oncology CGON|Earnings per share growth in current year UroGen URGN|Expected net earnings per share growth this year Bicara Bio (BCAX)|PSNL - Earnings per share growth in current year|ERAS - Earnings growth in current year|DCTH: Earnings growth in current year|Y-mAbs Therapeutics, Inc. (YMAB) - Earnings growth in current year|Net earnings per share growth this year AURA|Earnings per share growth rate in current year candeltx.com CADL|Earnings growth in current year ARAY|SLS (SELLAS Life Sciences Group, Inc.) - Earnings per share increase in current year|Earnings growth in current year ACTU (Actuate Therapeutics Inc)|Earnings per share increase in current year CTOR|tuhurabio.com - Earnings growth in current year|Earnings per share increase in current year TARA (Protara Therapeutics)|Fate Therapeutics, Inc. (FATE) - Earnings per share growth in current year|WHWK - Expected net earnings per share growth this year|Earnings per share growth in current year tscan.com|CSBR: Earnings per share increase in current year|Earnings per share growth in current year XBiotech USA (XBIT)|CVM: Earnings per share trend in current year|Earnings per share growth in current year ostherapies.com OSTX|Net earnings per one share growth for the current year RADX (Radiopharm Theranostics Limited)|Artiva - Earnings growth in current year|ANL: Earnings per share growth in current year|VERU: Earnings growth in current year|Earnings per share trend in current year TPST (Tempest Tx)|XLO (Xilio Therapeutics) - Earnings growth in current year|Earnings per share growth rate in current year renovarobio.com RENB|Earnings per share growth in current year muraloncology.com (MURA)|Net earnings per one share growth for the current year KAPA|Earnings growth in current year OKUR (onkuretherapeutics.com)|Net earnings per one share growth for the current year GDTC (CytoMed)|Curis - Earnings growth in current year|APLM: Earnings per share growth in current year|Tharimmune (THAR) - Earnings per share growth in current year|Net earnings per share growth this year Advanced Biomed Inc.|GNPX (Genprex Inc) - Earnings growth in current year|Calidi Biotherapeutics (CLDI) - Expected net earnings per share growth this year|Earnings growth in current year SBFM|Earnings per share growth in current year XBIO (Xenetic Biosciences, Inc.)|Earnings growth in current year SLRX (salariuspharma.com)|PPBT - Net earnings per share growth this year|AONC - Earnings per share growth in current year|Earnings per share increase in current year BGNE (BeOne Medicines)|CKPT: Earnings growth in current year|Elevation Oncology Inc. (ELEV) - Earnings growth in current year|ICAD (iCAD) - Earnings growth in current year|Earnings growth in current year ikenaoncology.com|Earnings growth in current year NTBL|Earnings growth in current year Viracta Therapeutics Inc. (VIRX)|Earnings per share growth in current year MorphoSys Inc MOR|Earnings per share increase in current year NAYA
